In addition, there were several cancer-critical genes encoding drug targets, including EGFR (located on chromosome arm 7p and gained in 51% of immune deficient MPNSTs), ERBB2 (17q: 40%), FGFR1 (8p: 51%), SMO (7q: 31%), and XPO1 (2p: 37%), in addition to EZH2 (29%); all with highest frequency of gain in immune deficient MPNSTs (OR>2.6, P < 0.06 from one-sided Fisher's exact test; Fig. 3c and Supplementary Table S3). Here, ERBB2 is linked to cancer.